tenofovir disoproxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals 2593 201341-05-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • viread
  • tenofovir disoproxil
  • tenofovir disoproxil fumarate
Tenofovir disoproxil fumarate is the fumarate salt of the prodrug tenofovir disoproxil. Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate (nucleotide) analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate has an intracellular half-life of 10 hours in activated and 50 hours in resting peripheral blood mononuclear cells (PBMCs). Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of cellular polymerases alpha, beta, and gamma. At concentrations of up to 300 umol/l, tenofovir has also shown no effect on the synthesis of mitochondrial DNA or the production of lactic acid in in vitro assays.
  • Molecular weight: 519.45
  • Formula: C19H30N5O10P
  • CLOGP: 0.80
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 1
  • TPSA: 185.44
  • ALOGS: -2.86
  • ROTB: 17
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 16.67 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 82 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.43 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0.25 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.942 Moderate 0.69
caco2-efflux Caco-2 efflux ratio (BA/AB) 4.786 Moderate 0.69
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 37.411 10^-6 cm/s Moderate 0.69
dh-clint Dog hepatocyte intrinsic clearance 142.561 uL/min/10^6 cells Moderate 0.69
dppb Dog plasma protein binding (% unbound) 29.520 % Moderate 0.69
fcs-ppb Fetal calf serum protein binding (% unbound) 19.420 % Moderate 0.69
herg hERG pIC50 4.305 pIC50 Moderate 0.69
hh-clint Human hepatocyte intrinsic clearance 316.228 uL/min/10^6 cells Moderate 0.69
hlm-clint Human liver microsomal intrinsic clearance 252.348 uL/min/mg protein Moderate 0.69
hppb Human plasma protein binding (% unbound) 19.490 % Moderate 0.69
kinase-safety-class ACVR2B,AXL,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,FLT3,GRK2,ITK,MAP3K21,MAPK7,PDK1,PDK2,PIK3CD,PRKDC 16
kinase-selectivity-class AXL,BRAF,CDK9,GRK2,MAP3K21 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.099 Moderate 0.69
mh-clint Mouse hepatocyte intrinsic clearance 619.441 Moderate 0.69
mppb Mouse plasma protein binding (% unbound) 25.610 Moderate 0.69
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 20.324 Moderate 0.69
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.69
pppb Pig plasma protein binding (% unbound) 22.380 % Moderate 0.69
rh-clint Rat hepatocyte intrinsic clearance 336.512 uL/min/10^6 cells Moderate 0.69
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.380 % Moderate 0.69
rppb Rat plasma protein binding (% unbound) 18.360 % Moderate 0.69
solubility-dd Solubility at pH 7.4 in DMSO 527.230 uM Moderate 0.69

Approvals:

DateAgencyCompanyOrphan
Oct. 26, 2001 FDA GILEAD SCIENCES INC
Feb. 4, 2002 EMA Gilead Sciences Ireland UC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abortion spontaneous 1418.70 18.44 499 18069 53557 90556322
Foetal exposure during pregnancy 699.46 18.44 280 18288 42695 90567184
Fanconi syndrome acquired 684.33 18.44 131 18437 1143 90608736
Exposure during pregnancy 652.36 18.44 472 18096 237938 90371941
Maternal exposure during pregnancy 572.72 18.44 519 18049 359544 90250335
Virologic failure 572.05 18.44 124 18444 2100 90607779
Stillbirth 499.33 18.44 141 18427 7302 90602577
Viral mutation identified 482.30 18.44 106 18462 1919 90607960
Abortion induced 362.23 18.44 123 18445 11765 90598114
Immune reconstitution inflammatory syndrome 351.55 18.44 106 18462 6913 90602966
Pregnancy 342.85 18.44 192 18376 61855 90548024
Drug resistance 333.78 18.44 150 18418 30299 90579580
Premature baby 302.07 18.44 132 18436 24945 90584934
Pathogen resistance 295.28 18.44 96 18472 8019 90601860
Blood HIV RNA increased 269.29 18.44 56 18512 768 90609111
Viral load increased 259.92 18.44 61 18507 1495 90608384
Fanconi syndrome 236.41 18.44 59 18509 1884 90607995
Osteoporosis 222.61 18.44 173 18395 96358 90513521
Caesarean section 214.67 18.44 95 18473 18482 90591397
Renal tubular disorder 211.61 18.44 60 18508 3147 90606732
Nephropathy toxic 207.25 18.44 83 18485 12605 90597274
Genotype drug resistance test positive 203.13 18.44 40 18528 409 90609470
Premature labour 189.44 18.44 79 18489 13297 90596582
Hepatitis B DNA increased 181.98 18.44 34 18534 256 90609623
Renal tubular acidosis 178.79 18.44 49 18519 2266 90607613
Premature delivery 176.88 18.44 106 18462 38656 90571223
Hypophosphataemia 171.74 18.44 76 18492 14778 90595101
Lipodystrophy acquired 159.61 18.44 41 18527 1473 90608406
Arthrodesis 157.32 18.44 47 18521 2965 90606914
Renal tubular dysfunction 156.86 18.44 33 18535 480 90609399
Acute kidney injury 148.19 18.44 248 18320 320139 90289740
Glycosuria 146.90 18.44 38 18530 1404 90608475
Hepatitis B reactivation 144.49 18.44 47 18521 3927 90605952
Enlarged clitoris 142.42 18.44 25 18543 126 90609753
Hyperandrogenism 141.05 18.44 24 18544 97 90609782
Osteomalacia 138.57 18.44 33 18535 862 90609017
Proteinuria 133.76 18.44 74 18494 23217 90586662
CD4 lymphocytes decreased 130.00 18.44 35 18533 1512 90608367
Renal failure 118.43 18.44 140 18428 130867 90479012
Hypophosphataemic osteomalacia 117.44 18.44 23 18545 228 90609651
Treatment noncompliance 115.44 18.44 91 18477 51636 90558243
Premature rupture of membranes 110.71 18.44 42 18526 5516 90604363
Hepatic cytolysis 109.46 18.44 72 18496 30844 90579035
Alanine aminotransferase increased 106.18 18.44 126 18442 118212 90491667
Rebound effect 102.02 18.44 46 18522 9338 90600541
Cushing's syndrome 101.33 18.44 24 18544 612 90609267
Foetal death 100.59 18.44 59 18509 20664 90589215
Hydrops foetalis 91.79 18.44 22 18546 591 90609288
Jaundice 89.82 18.44 65 18503 32452 90577427
Renal tubular necrosis 88.41 18.44 48 18520 14507 90595372
Joint swelling 80.31 18.44 6 18562 503294 90106585
Aspartate aminotransferase increased 80.04 18.44 102 18466 102835 90507044
Hyperbilirubinaemia 79.24 18.44 44 18524 13892 90595987
Drug interaction 78.30 18.44 174 18394 276279 90333600
Pain 77.61 18.44 55 18513 996286 89613593
Oligohydramnios 77.33 18.44 35 18533 7166 90602713
CSF HIV escape syndrome 76.20 18.44 14 18554 95 90609784
Osteonecrosis 76.02 18.44 54 18514 26187 90583692
Blood creatinine increased 74.97 18.44 98 18470 101288 90508591
Placental insufficiency 74.07 18.44 23 18545 1652 90608227
Ultrasound antenatal screen abnormal 72.90 18.44 14 18554 124 90609755
Placental disorder 70.73 18.44 22 18546 1589 90608290
Live birth 70.54 18.44 84 18484 79023 90530856
Infusion related reaction 69.33 18.44 4 18564 416776 90193103
Hepatitis B 68.40 18.44 28 18540 4491 90605388
Maternal drugs affecting foetus 68.14 18.44 29 18539 5126 90604753
Malaria 66.84 18.44 14 18554 199 90609680
Pre-eclampsia 65.89 18.44 36 18532 11012 90598867
Meningomyelocele 65.79 18.44 17 18551 625 90609254
Fatigue 65.10 18.44 85 18483 1153938 89455941
Placenta praevia 65.07 18.44 19 18549 1106 90608773
Haemolytic anaemia 63.97 18.44 36 18532 11661 90598218
Peripheral swelling 60.35 18.44 7 18561 413099 90196780
Shoulder arthroplasty 60.30 18.44 25 18543 4141 90605738
Nasopharyngitis 59.22 18.44 7 18561 407097 90202782
Hepatitis D 58.65 18.44 10 18558 41 90609838
Hepatitis fulminant 58.21 18.44 24 18544 3921 90605958
Renal colic 57.86 18.44 19 18549 1634 90608245
Systemic lupus erythematosus 55.79 18.44 5 18563 361891 90247988
Blood phosphorus decreased 55.75 18.44 25 18543 5009 90604870
Hemivertebra 55.37 18.44 11 18557 118 90609761
Congenital choroid plexus cyst 55.09 18.44 13 18555 326 90609553
Limb operation 55.02 18.44 24 18544 4503 90605376
Arnold-Chiari malformation 54.52 18.44 15 18553 703 90609176
Metabolic acidosis 54.44 18.44 62 18506 55614 90554265
Foetal growth restriction 54.38 18.44 30 18538 9350 90600529
Neonatal respiratory distress syndrome 53.11 18.44 21 18547 3080 90606799
Congenital umbilical hernia 50.00 18.44 12 18556 324 90609555
Immune reconstitution inflammatory syndrome associated tuberculosis 49.99 18.44 13 18555 490 90609389
Macrocephaly 49.82 18.44 11 18557 203 90609676
Antiviral drug level below therapeutic 49.52 18.44 9 18559 57 90609822
Ectopic pregnancy 48.78 18.44 20 18548 3221 90606658
Anaemia 47.93 18.44 170 18398 352632 90257247
Lactic acidosis 47.32 18.44 55 18513 50408 90559471
Sinusitis 47.25 18.44 7 18561 343081 90266798
Birth mark 46.18 18.44 10 18558 168 90609711
Gestational diabetes 45.82 18.44 28 18540 10554 90599325
Nephrogenic diabetes insipidus 45.77 18.44 14 18554 956 90608923
HIV infection 45.48 18.44 12 18556 479 90609400
Cleft lip and palate 44.75 18.44 13 18555 743 90609136
Stomatitis 44.56 18.44 3 18565 274695 90335184
Congenital hydrocephalus 44.21 18.44 10 18558 207 90609672
Ultrasound antenatal screen 43.80 18.44 10 18558 216 90609663
Patent ductus arteriosus 42.18 18.44 20 18548 4549 90605330
Ventricular septal defect 41.90 18.44 21 18547 5386 90604493
Musculoskeletal stiffness 40.94 18.44 6 18562 296526 90313353
Dyspnoea 40.82 18.44 74 18494 880881 89728998
Renal impairment 40.04 18.44 75 18493 105346 90504533
Swelling 39.86 18.44 18 18550 419040 90190839
Hepatitis B DNA assay positive 39.76 18.44 7 18561 36 90609843
Cholestasis of pregnancy 39.09 18.44 14 18554 1563 90608316
Drug reaction with eosinophilia and systemic symptoms 39.09 18.44 46 18522 42712 90567167
Transaminases increased 39.06 18.44 43 18525 37149 90572730
Acquired immunodeficiency syndrome 38.58 18.44 8 18560 108 90609771
Blood creatine phosphokinase MB increased 38.50 18.44 13 18555 1219 90608660
Hydromyelia 38.37 18.44 6 18562 12 90609867
Fall 38.17 18.44 26 18542 481784 90128095
Pulmonary tuberculosis 38.13 18.44 19 18549 4815 90605064
Foetal distress syndrome 38.03 18.44 14 18554 1691 90608188
AIDS cholangiopathy 37.45 18.44 6 18562 15 90609864
Human immunodeficiency virus transmission 37.43 18.44 7 18561 53 90609826
Adrenal suppression 36.95 18.44 12 18556 997 90608882
Discomfort 36.85 18.44 6 18562 274329 90335550
Hepatic failure 36.75 18.44 43 18525 39685 90570194
Chronic kidney disease 36.28 18.44 48 18520 50143 90559736
Congenital anomaly 35.97 18.44 20 18548 6327 90603552
Viral load decreased 35.72 18.44 6 18562 22 90609857
Rash maculo-papular 35.71 18.44 43 18525 40890 90568989
Drug intolerance 35.66 18.44 24 18544 447567 90162312
Multiple-drug resistance 34.76 18.44 21 18547 7755 90602124
Arthralgia 34.62 18.44 67 18501 778455 89831424
Spina bifida 34.41 18.44 11 18557 869 90609010
Blood creatine phosphokinase increased 33.44 18.44 38 18530 33985 90575894
Asthma 33.19 18.44 5 18563 242155 90367724
Retinal toxicity 32.91 18.44 12 18556 1410 90608469
Umbilical cord abnormality 32.85 18.44 10 18558 672 90609207
Polyhydramnios 32.79 18.44 14 18554 2494 90607385
Blood bilirubin increased 32.08 18.44 42 18526 43428 90566451
Oesophageal candidiasis 31.97 18.44 19 18549 6810 90603069
Impaired healing 31.73 18.44 5 18563 234194 90375685
Eyelid oedema 31.71 18.44 23 18545 11511 90598368
Blood cholesterol increased 31.70 18.44 3 18565 208009 90401870
Autoimmune hepatitis 31.60 18.44 22 18546 10329 90599550
Hepatitis 31.56 18.44 54 18514 70685 90539194
Blister 31.23 18.44 7 18561 254991 90354888
Lower respiratory tract infection 30.46 18.44 7 18561 250652 90359227
Polydactyly 30.38 18.44 8 18560 317 90609562
Sudden infant death syndrome 30.16 18.44 8 18560 326 90609553
Congenital pulmonary valve disorder 30.15 18.44 6 18562 65 90609814
Gamma-glutamyltransferase increased 30.09 18.44 38 18530 37914 90571965
Pneumonia 30.04 18.44 53 18515 638006 89971873
Hepatitis A 29.50 18.44 9 18559 609 90609270
Drug level below therapeutic 29.39 18.44 17 18551 5797 90604082
Rickets 29.36 18.44 6 18562 75 90609804
Hypoaesthesia 29.09 18.44 14 18554 314196 90295683
Small for dates baby 28.99 18.44 16 18552 4991 90604888
Arthropathy 28.67 18.44 20 18548 366222 90243657
Foetal cardiac disorder 28.51 18.44 5 18563 25 90609854
Product use in unapproved indication 28.17 18.44 17 18551 336219 90273660
Nephrolithiasis 28.12 18.44 42 18526 49043 90560836
Melanoderma 27.97 18.44 7 18561 226 90609653
Lipohypertrophy 27.92 18.44 9 18559 730 90609149
Vaginal ulceration 27.77 18.44 8 18560 444 90609435
Hepatotoxicity 27.38 18.44 40 18528 45802 90564077
Ill-defined disorder 27.31 18.44 3 18565 184888 90424991
Portal hypertension 27.15 18.44 15 18553 4686 90605193
Abortion infected 27.08 18.44 5 18563 35 90609844
Twin pregnancy 26.96 18.44 10 18558 1233 90608646
Mobility decreased 26.74 18.44 9 18559 250725 90359154
Ocular icterus 26.62 18.44 14 18554 3966 90605913
HIV-associated neurocognitive disorder 26.18 18.44 6 18562 132 90609747
Acidosis hyperchloraemic 26.12 18.44 9 18559 897 90608982
Hydrocephalus 26.06 18.44 16 18552 6078 90603801
Product use issue 25.84 18.44 18 18550 329901 90279978
Condition aggravated 25.80 18.44 52 18516 595493 90014386
HIV test positive 25.67 18.44 5 18563 48 90609831
Type III hyperlipidaemia 25.58 18.44 4 18564 8 90609871
Trisomy 18 25.56 18.44 6 18562 147 90609732
Off label use 25.42 18.44 128 18440 1102124 89507755
Neonatal respiratory arrest 25.40 18.44 5 18563 51 90609828
Coarctation of the aorta 25.22 18.44 8 18560 616 90609263
Cloacal exstrophy 25.07 18.44 6 18562 160 90609719
Chronic papillomatous dermatitis 24.97 18.44 5 18563 56 90609823
Congenital teratoma 24.97 18.44 4 18564 10 90609869
Albuminuria 24.93 18.44 7 18561 354 90609525
Dermatitis exfoliative 24.87 18.44 15 18553 5521 90604358
Congenital genital malformation 24.83 18.44 6 18562 167 90609712
Dry mouth 24.77 18.44 4 18564 184055 90425824
Hepatitis C 24.56 18.44 15 18553 5645 90604234
Congenital knee dislocation 24.43 18.44 4 18564 12 90609867
Ectopic kidney 24.29 18.44 5 18563 65 90609814
Benign hydatidiform mole 24.24 18.44 6 18562 185 90609694
Caudal regression syndrome 23.99 18.44 6 18562 193 90609686
Blood bilirubin unconjugated increased 23.93 18.44 7 18561 410 90609469
Constipation 23.73 18.44 14 18554 280381 90329498
Cholestasis 23.63 18.44 33 18535 36266 90573613
Alopecia 23.39 18.44 41 18527 495030 90114849
Hyperparathyroidism secondary 23.37 18.44 10 18558 1791 90608088
Trisomy 21 23.28 18.44 7 18561 451 90609428
Blood alkaline phosphatase increased 23.17 18.44 38 18530 48041 90561838
Cough 23 18.44 25 18543 368937 90240942
ACTH stimulation test abnormal 22.98 18.44 4 18564 19 90609860
Injection site pain 22.87 18.44 4 18564 173695 90436184
Face oedema 22.84 18.44 26 18542 23292 90586587
Normal newborn 22.80 18.44 26 18542 23336 90586543
Osteoarthritis 22.74 18.44 6 18562 195724 90414155
Headache 22.33 18.44 96 18472 862650 89747229
Hypouricaemia 22.31 18.44 6 18562 258 90609621
Gene mutation 21.76 18.44 10 18558 2120 90607759
Eosinophilia 21.72 18.44 28 18540 28505 90581374
Atrial septal defect 21.69 18.44 16 18552 8218 90601661
Thymus hypoplasia 21.42 18.44 4 18564 30 90609849
Hypersensitivity 21.16 18.44 38 18530 454639 90155240
Tubulointerstitial nephritis 21.09 18.44 26 18542 25317 90584562
Pulmonary valve sclerosis 20.98 18.44 4 18564 34 90609845
Pancytopenia 20.82 18.44 63 18505 120200 90489679
Premature separation of placenta 20.77 18.44 10 18558 2352 90607527
Mitochondrial toxicity 20.73 18.44 7 18561 656 90609223
Ascites 20.71 18.44 36 18532 47704 90562175
Malaise 20.71 18.44 57 18511 585929 90023950
Pregnancy on oral contraceptive 20.68 18.44 8 18560 1107 90608772
Liver function test abnormal 20.33 18.44 37 18531 50808 90559071
Hepatic function abnormal 20.20 18.44 35 18533 46253 90563626
Bladder agenesis 20.20 18.44 5 18563 154 90609725
Amniorrhoea 20.20 18.44 5 18563 154 90609725
Hepatic encephalopathy 20.06 18.44 19 18549 13753 90596126
Migraine 20.01 18.44 7 18561 190385 90419494
Genitalia external ambiguous 19.99 18.44 5 18563 161 90609718
Hyperbilirubinaemia neonatal 19.90 18.44 6 18562 390 90609489
Chronic hepatitis B 19.87 18.44 6 18562 392 90609487
Low birth weight baby 19.71 18.44 16 18552 9451 90600428
Arthritis 19.68 18.44 5 18563 167310 90442569
Alpha 1 foetoprotein abnormal 19.65 18.44 4 18564 49 90609830
Sleep disorder 19.61 18.44 8 18560 198022 90411857
Memory impairment 19.48 18.44 8 18560 197236 90412643
Lip oedema 19.38 18.44 12 18556 4627 90605252
Gait disturbance 19.37 18.44 15 18553 260481 90349398
Generalised anxiety disorder 19.34 18.44 10 18558 2737 90607142
Growth hormone-producing pituitary tumour 19.19 18.44 3 18565 6 90609873
Carbon dioxide combining power abnormal 19.19 18.44 3 18565 6 90609873
Glycocholic acid increased 19.19 18.44 3 18565 6 90609873
Anal atresia 19.15 18.44 6 18562 444 90609435
Mental disability 19.04 18.44 5 18563 196 90609683
Therapeutic product effect incomplete 18.93 18.44 8 18560 193888 90415991
Blood HIV RNA 18.87 18.44 3 18565 7 90609872
Rash 18.80 18.44 247 18321 795853 89814026
Meconium stain 18.73 18.44 5 18563 209 90609670
Ankyloglossia congenital 18.55 18.44 5 18563 217 90609662

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Virologic failure 1108.92 13.22 309 33711 3685 42583630
Immune reconstitution inflammatory syndrome 997.03 13.22 355 33665 9788 42577527
Fanconi syndrome acquired 937.42 13.22 236 33784 1834 42585481
Viral mutation identified 894.01 13.22 251 33769 3080 42584235
Pathogen resistance 736.81 13.22 294 33726 11156 42576159
Lipodystrophy acquired 630.48 13.22 193 33827 3257 42584058
Mitochondrial toxicity 485.08 13.22 148 33872 2467 42584848
Osteoporosis 460.83 13.22 229 33791 14677 42572638
Renal tubular disorder 434.09 13.22 159 33861 4750 42582565
Fanconi syndrome 377.87 13.22 112 33908 1682 42585633
Hepatitis B 372.27 13.22 155 33865 6556 42580759
Foetal exposure during pregnancy 368.86 13.22 304 33716 47007 42540308
Viral load increased 364.22 13.22 123 33897 2874 42584441
Drug resistance 342.53 13.22 255 33765 33993 42553322
Eyelid ptosis 316.96 13.22 138 33882 6523 42580792
Blood HIV RNA increased 269.49 13.22 84 33936 1507 42585808
Progressive external ophthalmoplegia 253.76 13.22 78 33942 1333 42585982
Nephropathy toxic 230.42 13.22 152 33868 16686 42570629
Genotype drug resistance test positive 226.93 13.22 69 33951 1135 42586180
Osteomalacia 202.90 13.22 59 33961 825 42586490
Hypophosphataemia 196.10 13.22 150 33870 20795 42566520
Glycosuria 193.54 13.22 63 33957 1307 42586008
Acquired gene mutation 188.64 13.22 64 33956 1516 42585799
Diplopia 178.23 13.22 140 33880 20176 42567139
Renal tubular dysfunction 177.20 13.22 46 33974 408 42586907
Hepatitis B DNA increased 174.55 13.22 48 33972 541 42586774
Blood phosphorus decreased 172.74 13.22 75 33945 3518 42583797
Proteinuria 169.22 13.22 143 33877 22840 42564475
Osteonecrosis 162.69 13.22 120 33900 15745 42571570
Blood creatinine increased 160.79 13.22 303 33717 109700 42477615
Hepatitis B reactivation 158.38 13.22 76 33944 4502 42582813
Tearfulness 158.34 13.22 70 33950 3430 42583885
Depression suicidal 156.86 13.22 68 33952 3177 42584138
Depressive symptom 151.90 13.22 70 33950 3783 42583532
Psychiatric decompensation 151.89 13.22 72 33948 4150 42583165
CD4 lymphocytes decreased 147.06 13.22 56 33964 1865 42585450
Renal colic 136.03 13.22 54 33966 2014 42585301
Renal failure 131.96 13.22 328 33692 143398 42443917
Psychomotor skills impaired 129.11 13.22 69 33951 5135 42582180
Renal impairment 128.04 13.22 276 33744 109952 42477363
Renal tubular acidosis 127.63 13.22 56 33964 2694 42584621
Hepatic failure 115.23 13.22 147 33873 37953 42549362
Exposure during pregnancy 111.68 13.22 75 33945 8473 42578842
Treatment failure 111.31 13.22 188 33832 62436 42524879
Jaundice 103.88 13.22 133 33887 34456 42552859
HIV-associated neurocognitive disorder 96.86 13.22 27 33993 321 42586994
Alanine aminotransferase increased 96.53 13.22 216 33804 88190 42499125
Pneumonia 94.80 13.22 119 33901 422030 42165285
Osteopenia 94.02 13.22 60 33960 6218 42581097
Hepatic cirrhosis 91.68 13.22 95 33925 19607 42567708
Volvulus 90.22 13.22 40 33980 1973 42585342
Off label use 89.16 13.22 241 33779 638094 41949221
Renal tubular necrosis 84.50 13.22 88 33932 18266 42569049
Hepatitis B DNA assay positive 82.96 13.22 18 34002 65 42587250
Paranoia 82.74 13.22 77 33943 13949 42573366
Acquired immunodeficiency syndrome 82.60 13.22 26 33994 482 42586833
Chronic kidney disease 80.20 13.22 139 33881 47102 42540213
Hepatocellular carcinoma 79.56 13.22 60 33960 8134 42579181
Premature baby 79.10 13.22 95 33925 23058 42564257
Dyspnoea 77.15 13.22 148 33872 442473 42144842
Aspartate aminotransferase increased 77 13.22 182 33838 76981 42510334
Nephrolithiasis 76.90 13.22 119 33901 36711 42550604
Lactic acidosis 76.61 13.22 133 33887 45128 42542187
Drug interaction 75.29 13.22 415 33605 266584 42320731
Kaposi's sarcoma 74.91 13.22 27 33993 768 42586547
Multiple-drug resistance 74.18 13.22 55 33965 7267 42580048
Acute HIV infection 74.13 13.22 16 34004 56 42587259
Trisomy 21 71.15 13.22 24 33996 558 42586757
Osteoporotic fracture 70.86 13.22 31 33989 1480 42585835
Acute kidney injury 70.18 13.22 517 33503 366820 42220495
Treatment noncompliance 68.10 13.22 114 33906 37558 42549757
Mitochondrial cytopathy 66.18 13.22 17 34003 144 42587171
Ophthalmoplegia 65.57 13.22 33 33987 2167 42585148
Febrile neutropenia 64.36 13.22 34 33986 185669 42401646
Portal hypertension 62.52 13.22 42 33978 4745 42582570
Hepatitis 62.37 13.22 92 33928 27208 42560107
Glomerular filtration rate decreased 62.36 13.22 71 33949 16280 42571035
Brain stem stroke 61.51 13.22 19 34001 330 42586985
Lipoatrophy 60.98 13.22 20 34000 425 42586890
Death 59.67 13.22 186 33834 470999 42116316
Psychotic disorder 59.06 13.22 93 33927 29115 42558200
HIV infection 58.59 13.22 27 33993 1458 42585857
Malignant neoplasm progression 57.24 13.22 9 34011 108391 42478924
Gene mutation 56.88 13.22 28 33992 1753 42585562
Hepatic cytolysis 56.40 13.22 87 33933 26757 42560558
Hypophosphataemic osteomalacia 55.63 13.22 15 34005 156 42587159
Product dose omission issue 55.36 13.22 27 33993 154338 42432977
Creatinine renal clearance decreased 55.27 13.22 35 33985 3578 42583737
Hypotension 52.27 13.22 78 33942 257553 42329762
Disease progression 51.71 13.22 25 33995 143631 42443684
Ultrasound antenatal screen 48.85 13.22 18 34002 546 42586769
Congenital umbilical hernia 48.78 13.22 16 34004 340 42586975
Beta 2 microglobulin urine increased 48.60 13.22 12 34008 85 42587230
Anal cancer 48.39 13.22 17 34003 448 42586867
Syphilis 48.30 13.22 18 34002 564 42586751
CSF HIV escape syndrome 48.25 13.22 14 34006 194 42587121
Blood lactic acid increased 47.15 13.22 44 33976 7995 42579320
Varices oesophageal 46.96 13.22 34 33986 4331 42582984
COVID-19 46.83 13.22 17 34003 115931 42471384
Cleft lip and palate 46.58 13.22 20 34000 912 42586403
Hyperbilirubinaemia 46.36 13.22 69 33951 20566 42566749
Blood bilirubin increased 45.79 13.22 103 33917 42149 42545166
Cytomegalovirus chorioretinitis 45.29 13.22 34 33986 4577 42582738
Suicidal ideation 45.22 13.22 111 33909 48050 42539265
Blood creatine phosphokinase increased 43.90 13.22 110 33910 48228 42539087
Lymphoma 42.87 13.22 55 33965 14266 42573049
Fall 41.97 13.22 77 33943 234443 42352872
Blood phosphorus abnormal 41.93 13.22 12 34008 158 42587157
Trisomy 18 41.39 13.22 18 34002 847 42586468
Atrial fibrillation 40.86 13.22 31 33989 139562 42447753
Constipation 40.35 13.22 42 33978 162249 42425066
Hepatic steatosis 40.22 13.22 66 33954 21382 42565933
Hyperphosphaturia 39.77 13.22 10 34010 77 42587238
Brachydactyly 39.76 13.22 12 34008 192 42587123
Hepatic cancer 39.64 13.22 41 33979 8439 42578876
Hepatitis C 38.63 13.22 44 33976 10089 42577226
Peripheral swelling 38.60 13.22 12 34008 90258 42497057
Congenital hearing disorder 38.19 13.22 10 34010 92 42587223
Blood pressure increased 37.80 13.22 17 34003 101911 42485404
Hydrops foetalis 37.42 13.22 17 34003 888 42586427
Congenital anomaly 37.01 13.22 20 34000 1521 42585794
Drug abuse 36.53 13.22 19 34001 104752 42482563
Blood alkaline phosphatase increased 36.51 13.22 82 33938 33515 42553800
Oesophageal atresia 35.44 13.22 14 34006 515 42586800
Polydactyly 35.29 13.22 18 34002 1216 42586099
HIV wasting syndrome 35.16 13.22 9 34011 75 42587240
Joint swelling 35.11 13.22 6 34014 68016 42519299
Infusion related reaction 34.58 13.22 4 34016 60802 42526513
Hemivertebra 34.57 13.22 10 34010 137 42587178
Completed suicide 34.37 13.22 17 34003 96448 42490867
Inappropriate schedule of product administration 34.02 13.22 17 34003 95885 42491430
Fatigue 33.65 13.22 207 33813 435434 42151881
Pain 33.53 13.22 93 33927 244755 42342560
Birth mark 33.08 13.22 10 34010 161 42587154
Dysphagia 32.94 13.22 130 33890 72589 42514726
Dyslipidaemia 32.74 13.22 39 33981 9379 42577936
Maternal drugs affecting foetus 32.67 13.22 26 33994 3813 42583502
Hepatitis D 32.36 13.22 8 34012 57 42587258
Nodular regenerative hyperplasia 32.06 13.22 16 34004 1032 42586283
Pulmonary tuberculosis 32.05 13.22 30 33990 5471 42581844
Nephropathy 31.56 13.22 33 33987 6878 42580437
Oesophageal candidiasis 31.44 13.22 30 33990 5605 42581710
Toxicity to various agents 31.39 13.22 87 33933 229049 42358266
Nasopharyngitis 31.16 13.22 14 34006 83982 42503333
Anogenital warts 31.00 13.22 14 34006 721 42586594
Sepsis 30.93 13.22 71 33949 199263 42388052
Ocular icterus 30.75 13.22 23 33997 3078 42584237
Bone pain 30.38 13.22 62 33958 23730 42563585
Hepatosplenomegaly 30.25 13.22 27 33993 4633 42582682
Wheezing 30.18 13.22 4 34016 54777 42532538
Laryngomalacia 30.06 13.22 11 34009 327 42586988
Scrotal cyst 29.59 13.22 9 34011 148 42587167
Hodgkin's disease 29.41 13.22 14 34006 814 42586501
Porphyria non-acute 29.38 13.22 12 34008 482 42586833
HIV test positive 29.05 13.22 9 34011 158 42587157
Blood antidiuretic hormone increased 28.80 13.22 7 34013 46 42587269
Lymphadenopathy 28.29 13.22 74 33946 33291 42554024
Progressive multifocal leukoencephalopathy 27.97 13.22 40 33980 11496 42575819
Peritoneal cyst 27.80 13.22 6 34014 21 42587294
Hydrocele 27.51 13.22 20 34000 2563 42584752
Hypertriglyceridaemia 27.38 13.22 37 33983 10089 42577226
Cardiac failure 27.29 13.22 27 33993 106829 42480486
Cachexia 27.25 13.22 33 33987 8071 42579244
Oxygen saturation decreased 26.94 13.22 9 34011 64678 42522637
Liver disorder 26.81 13.22 81 33939 39563 42547752
Dialysis 26.80 13.22 40 33980 11946 42575369
Infection 26.73 13.22 30 33990 112038 42475277
Diaphragmatic hernia 26.51 13.22 10 34010 324 42586991
Developmental hip dysplasia 26.31 13.22 10 34010 331 42586984
Meningomyelocele 26.22 13.22 9 34011 221 42587094
Injection site pain 25.96 13.22 7 34013 57791 42529524
Back pain 25.82 13.22 46 33974 141730 42445585
CSF virus identified 25.60 13.22 6 34014 33 42587282
Hepatic fibrosis 25.42 13.22 25 33995 4847 42582468
Pulmonary embolism 25.41 13.22 35 33985 119577 42467738
Talipes 25.39 13.22 18 34002 2218 42585097
Haemophilic arthropathy 25.20 13.22 9 34011 249 42587066
Plasma cell myeloma 24.99 13.22 4 34016 47574 42539741
Pulmonary oedema 24.79 13.22 6 34014 53266 42534049
Abortion spontaneous 24.67 13.22 10 34010 394 42586921
Gamma-glutamyltransferase increased 24.47 13.22 69 33951 32428 42554887
Retroviral rebound syndrome 24.28 13.22 5 34015 13 42587302
Retroperitoneal disorder 24.12 13.22 6 34014 44 42587271
Musculoskeletal stiffness 24.12 13.22 8 34012 57757 42529558
Cerebral toxoplasmosis 24.08 13.22 17 34003 2081 42585234
Product use issue 23.81 13.22 16 34004 76735 42510580
Hepatitis B e antigen positive 23.66 13.22 6 34014 48 42587267
Oesophageal varices haemorrhage 23.61 13.22 21 33999 3586 42583729
Hepatorenal syndrome 23.58 13.22 19 34001 2835 42584480
Cerebellar syndrome 23.58 13.22 19 34001 2836 42584479
AIDS related complication 23.51 13.22 5 34015 16 42587299
Protein urine present 23.50 13.22 26 33994 5775 42581540
Myalgia 23.48 13.22 144 33876 95936 42491379
Epistaxis 23.46 13.22 12 34008 66814 42520501
Nervous system disorder 23.37 13.22 46 33974 17149 42570166
Bone density decreased 23.31 13.22 17 34003 2189 42585126
Mitochondrial myopathy 23.28 13.22 8 34012 197 42587118
Pneumonitis 23.09 13.22 3 34017 41715 42545600
Burkitt's lymphoma 22.91 13.22 7 34013 117 42587198
Atypical mycobacterial infection 22.83 13.22 14 34006 1352 42585963
Congenital skin dimples 22.62 13.22 8 34012 215 42587100
Haemodialysis 22.60 13.22 34 33986 10226 42577089
Cardiac failure congestive 22.58 13.22 21 33999 85581 42501734
HIV associated nephropathy 22.43 13.22 9 34011 345 42586970
Hepatic function abnormal 22.40 13.22 91 33929 51476 42535839
Cryptorchism 22.28 13.22 16 34004 2011 42585304
Acute hepatitis C 22.22 13.22 7 34013 130 42587185
Somnolence 22.08 13.22 50 33970 141055 42446260
Drug ineffective for unapproved indication 21.88 13.22 5 34015 46158 42541157
Polydipsia 21.52 13.22 22 33998 4466 42582849
Bradycardia 21.36 13.22 22 33998 85462 42501853
End stage AIDS 21.26 13.22 5 34015 28 42587287
Asymptomatic viral hepatitis 21.26 13.22 5 34015 28 42587287
Cough 21.25 13.22 72 33948 178031 42409284
Immune reconstitution inflammatory syndrome associated tuberculosis 21.18 13.22 10 34010 571 42586744
Acute respiratory failure 21.02 13.22 3 34017 38855 42548460
Blood triglycerides increased 20.98 13.22 42 33978 15854 42571461
Liver function test abnormal 20.80 13.22 65 33955 32326 42554989
Ultrasound antenatal screen abnormal 20.76 13.22 6 34014 82 42587233
Influenza 20.61 13.22 12 34008 62163 42525152
Stress 20.53 13.22 5 34015 44207 42543108
Abnormal dreams 20.53 13.22 29 33991 8242 42579073
Lower respiratory tract infection 20.48 13.22 4 34016 41202 42546113
Polyuria 20.40 13.22 32 33988 9979 42577336
Thrombosis 20.31 13.22 15 34005 68496 42518819
Kidney fibrosis 20.15 13.22 17 34003 2705 42584610
Chest discomfort 20.09 13.22 13 34007 63603 42523712
Supernumerary nipple 19.94 13.22 5 34015 38 42587277
Secondary syphilis 19.94 13.22 6 34014 95 42587220
Interstitial lung disease 19.83 13.22 20 34000 78442 42508873
Haematochezia 19.77 13.22 11 34009 58425 42528890
Blood pressure decreased 19.71 13.22 11 34009 58321 42528994
Incorrect dose administered 19.38 13.22 9 34011 52965 42534350
Renal aneurysm 19.29 13.22 7 34013 203 42587112
Seroconversion test positive 19.26 13.22 4 34016 11 42587304
Portal fibrosis 19.21 13.22 8 34012 338 42586977
Therapeutic product effect incomplete 19.19 13.22 17 34003 70922 42516393
Adrenogenital syndrome 18.90 13.22 5 34015 48 42587267
Cytokine release syndrome 18.88 13.22 6 34014 44521 42542794
Polyneuropathy chronic 18.54 13.22 5 34015 52 42587263
Ankyloglossia congenital 18.52 13.22 8 34012 370 42586945
Pancreatitis 18.51 13.22 76 33944 43192 42544123
Perihepatic discomfort 18.40 13.22 3 34017 0 42587315
Ventricular septal defect 18.31 13.22 20 34000 4379 42582936
Protrusion tongue 18.30 13.22 7 34013 236 42587079
Cushing's syndrome 18.28 13.22 8 34012 382 42586933
Tubulointerstitial nephritis 18.17 13.22 61 33959 31487 42555828
Pleural effusion 18.16 13.22 31 33989 97135 42490180
Hyperhidrosis 17.73 13.22 28 33992 90484 42496831
Hepatic encephalopathy 17.71 13.22 40 33980 16402 42570913
Pneumocystis jirovecii pneumonia 17.54 13.22 52 33968 25129 42562186
Meningitis cryptococcal 17.41 13.22 17 34003 3266 42584049
Anion gap abnormal 17.41 13.22 8 34012 429 42586886
Congenital naevus 17.39 13.22 4 34016 20 42587295
Microalbuminuria 17.33 13.22 10 34010 864 42586451
Musculoskeletal toxicity 17.30 13.22 6 34014 152 42587163
Cranial nerve palsies multiple 17.19 13.22 5 34015 70 42587245
Mucosal inflammation 17.13 13.22 9 34011 49365 42537950
Blood bicarbonate decreased 17.09 13.22 16 34004 2919 42584396
Pleocytosis 17.01 13.22 9 34011 656 42586659
Meningitis tuberculous 16.83 13.22 9 34011 670 42586645
Lipohypertrophy 16.80 13.22 7 34013 296 42587019
Hepatitis cholestatic 16.78 13.22 29 33991 9795 42577520
Congenital tuberculosis 16.77 13.22 4 34016 24 42587291
Mycobacterium avium complex infection 16.67 13.22 16 34004 3011 42584304
Rhabdomyolysis 16.64 13.22 113 33907 77906 42509409
Amyotrophy 16.63 13.22 8 34012 476 42586839
Cardiogenic shock 16.61 13.22 4 34016 35636 42551679
Lymphocytic infiltration 16.59 13.22 10 34010 936 42586379
Micrognathia 16.56 13.22 7 34013 307 42587008
Viral load 16.45 13.22 5 34015 82 42587233
Antiviral drug level below therapeutic 16.33 13.22 3 34017 3 42587312
Congenital gastric anomaly 16.33 13.22 3 34017 3 42587312
Relapsing fever 16.31 13.22 6 34014 181 42587134
Low set ears 16.25 13.22 8 34012 501 42586814
CSF glucose decreased 16.24 13.22 4 34016 28 42587287
Malaise 16.21 13.22 101 33919 212055 42375260
Pneumonia aspiration 16.13 13.22 10 34010 50068 42537247
White matter lesion 16.10 13.22 10 34010 988 42586327
Portal vein thrombosis 16.08 13.22 19 34001 4530 42582785
Retinal toxicity 15.99 13.22 8 34012 519 42586796
Sinusitis 15.86 13.22 9 34011 47283 42540032
Renal disorder 15.78 13.22 55 33965 28925 42558390
Tachycardia 15.66 13.22 36 33984 101051 42486264
Asthma 15.61 13.22 16 34004 62298 42525017
Viral load decreased 15.56 13.22 4 34016 34 42587281
Dizziness 15.48 13.22 126 33894 249128 42338187
Creatinine renal clearance abnormal 15.47 13.22 7 34013 362 42586953
Small for dates baby 15.41 13.22 20 34000 5243 42582072
Intentional product misuse 15.38 13.22 16 34004 61884 42525431
Hepatomegaly 15.38 13.22 31 33989 11754 42575561
Pathological fracture 15.32 13.22 20 34000 5273 42582042
Transient ischaemic attack 15.31 13.22 4 34016 33735 42553580
Caesarean section 15.28 13.22 13 34007 2093 42585222
Haemoptysis 15.18 13.22 9 34011 46158 42541157
Calculus urinary 15.17 13.22 12 34008 1745 42585570
Laryngeal erythema 15.11 13.22 3 34017 6 42587309
Psychomotor retardation 14.93 13.22 18 34002 4381 42582934
Hepatitis B surface antibody positive 14.79 13.22 5 34015 117 42587198
Neck deformity 14.71 13.22 5 34015 119 42587196
Muscle spasms 14.70 13.22 29 33991 86015 42501300
White blood cell count increased 14.53 13.22 9 34011 45078 42542237
Renal infarct 14.43 13.22 12 34008 1871 42585444
Congenital diaphragmatic hernia 14.39 13.22 6 34014 254 42587061
CD4 lymphocytes abnormal 14.32 13.22 4 34016 48 42587267
Prostate cancer 14.26 13.22 9 34011 44634 42542681
Eagle Barrett syndrome 14.25 13.22 3 34017 9 42587306
Vth nerve injury 14.25 13.22 3 34017 9 42587306
Haemoglobin decreased 14.18 13.22 56 33964 132415 42454900
Optic neuritis 14.15 13.22 17 34003 4125 42583190
Syncope 14.15 13.22 37 33983 99369 42487946
Cellulitis 14.12 13.22 17 34003 61568 42525747
C-reactive protein increased 14.10 13.22 18 34002 63542 42523773
Pharyngeal cancer 14.09 13.22 4 34016 51 42587264
Drug dependence 14.09 13.22 3 34017 29091 42558224
Anogenital dysplasia 14.05 13.22 5 34015 137 42587178
Rhinorrhoea 13.99 13.22 4 34016 31790 42555525
Femoral neck fracture 13.93 13.22 17 34003 4192 42583123
Hypouricaemia 13.80 13.22 6 34014 282 42587033
Neonatal asphyxia 13.78 13.22 7 34013 469 42586846
International normalised ratio increased 13.69 13.22 11 34009 48157 42539158
Hypomagnesaemia 13.67 13.22 3 34017 28485 42558830
Splenomegaly 13.63 13.22 37 33983 17010 42570305
Hepatitis B surface antibody 13.58 13.22 3 34017 12 42587303
Hepatitis B core antibody 13.58 13.22 3 34017 12 42587303
VIIIth nerve injury 13.58 13.22 3 34017 12 42587303
Urticaria 13.49 13.22 24 33996 74012 42513303
CD4 lymphocytes increased 13.38 13.22 5 34015 158 42587157
Optic nerve cupping 13.37 13.22 4 34016 62 42587253
Portal venous gas 13.33 13.22 7 34013 502 42586813
Blood pressure systolic increased 13.31 13.22 3 34017 27965 42559350
Transaminases abnormal 13.27 13.22 6 34014 310 42587005

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fanconi syndrome acquired 1338.75 14.32 290 38448 2744 110547817
Virologic failure 1305.75 14.32 311 38427 4641 110545920
Immune reconstitution inflammatory syndrome 1275.21 14.32 392 38346 15834 110534727
Abortion spontaneous 1040.97 14.32 407 38331 33875 110516686
Viral mutation identified 912.49 14.32 228 38510 4191 110546370
Lipodystrophy acquired 798.83 14.32 206 38532 4318 110546243
Pathogen resistance 775.42 14.32 275 38463 17397 110533164
Drug resistance 575.51 14.32 314 38424 56060 110494501
Blood HIV RNA increased 569.30 14.32 136 38602 2052 110548509
Mitochondrial toxicity 569.17 14.32 147 38591 3098 110547463
Fanconi syndrome 538.27 14.32 143 38595 3376 110547185
Viral load increased 491.26 14.32 132 38606 3258 110547303
Renal tubular disorder 485.49 14.32 156 38582 7273 110543288
Nephropathy toxic 481.77 14.32 221 38517 27257 110523304
Hepatitis B 400.46 14.32 144 38594 9468 110541093
Stillbirth 386.19 14.32 115 38623 4149 110546412
Osteoporosis 378.54 14.32 283 38455 86869 110463692
Exposure during pregnancy 371.43 14.32 370 38368 167054 110383507
Genotype drug resistance test positive 368.92 14.32 88 38650 1318 110549243
Eyelid ptosis 327.47 14.32 136 38602 13191 110537370
Hepatitis B reactivation 326.41 14.32 116 38622 7368 110543193
Progressive external ophthalmoplegia 316.87 14.32 78 38660 1342 110549219
Hypophosphataemia 308.82 14.32 174 38564 33008 110517553
Abortion induced 303.76 14.32 112 38626 7907 110542654
Glycosuria 282.60 14.32 81 38657 2549 110548012
Maternal exposure during pregnancy 281.40 14.32 394 38344 254489 110296072
Proteinuria 276.09 14.32 173 38565 39845 110510716
Renal tubular dysfunction 271.81 14.32 63 38675 827 110549734
Hepatitis B DNA increased 258.35 14.32 60 38678 795 110549766
CD4 lymphocytes decreased 242.58 14.32 74 38664 2900 110547661
Osteomalacia 230.89 14.32 62 38676 1525 110549036
Renal tubular acidosis 224.41 14.32 78 38660 4637 110545924
Blood creatinine increased 221.78 14.32 296 38442 182593 110367968
Acquired gene mutation 205.49 14.32 64 38674 2690 110547871
Acute kidney injury 200.70 14.32 581 38157 634849 109915712
Psychiatric decompensation 190.98 14.32 73 38665 5692 110544869
Depression suicidal 188.70 14.32 69 38669 4755 110545806
Diplopia 188.39 14.32 139 38599 41755 110508806
Renal failure 182.93 14.32 303 38435 226271 110324290
Jaundice 179.69 14.32 156 38582 59080 110491481
Drug interaction 176.12 14.32 476 38262 499707 110050854
Renal impairment 175.46 14.32 269 38469 188176 110362385
Alanine aminotransferase increased 174.88 14.32 265 38473 183508 110367053
Tearfulness 173.38 14.32 73 38665 7322 110543239
Hypophosphataemic osteomalacia 171.72 14.32 38 38700 399 110550162
Treatment noncompliance 170.35 14.32 166 38572 72824 110477737
Psychomotor skills impaired 169.92 14.32 71 38667 6987 110543574
Caesarean section 169.27 14.32 87 38651 13730 110536831
Osteonecrosis 167.79 14.32 119 38619 33622 110516939
Blood phosphorus decreased 164.27 14.32 71 38667 7594 110542967
Aspartate aminotransferase increased 164.17 14.32 239 38499 159697 110390864
Foetal exposure during pregnancy 162.42 14.32 70 38668 7435 110543126
Chronic kidney disease 158.70 14.32 163 38575 76128 110474433
Depressive symptom 154.74 14.32 70 38668 8344 110542217
Hepatic failure 145.03 14.32 148 38590 68591 110481970
Renal tubular necrosis 143.54 14.32 104 38634 30371 110520190
CSF HIV escape syndrome 123.65 14.32 28 38710 329 110550232
Joint swelling 120.78 14.32 9 38729 442836 110107725
Pregnancy 118.87 14.32 116 38622 50951 110499610
Renal colic 117.86 14.32 44 38694 3214 110547347
Paranoia 109.13 14.32 78 38660 22296 110528265
Lactic acidosis 107.48 14.32 147 38591 92664 110457897
Infusion related reaction 106.09 14.32 7 38731 381155 110169406
HIV-associated neurocognitive disorder 104.26 14.32 25 38713 383 110550178
Multiple-drug resistance 103.46 14.32 62 38676 13173 110537388
Hepatocellular carcinoma 103.39 14.32 56 38682 9824 110540737
Pain 101.71 14.32 111 38627 954844 109595717
Hepatic cytolysis 100.92 14.32 110 38628 54943 110495618
Arthrodesis 99.39 14.32 37 38701 2681 110547880
Premature labour 98.81 14.32 53 38685 9119 110541442
Blood bilirubin increased 93.56 14.32 124 38614 75848 110474713
Hyperbilirubinaemia 93.44 14.32 81 38657 30590 110519971
Nephrolithiasis 90.83 14.32 114 38624 66098 110484463
Ultrasound antenatal screen 90.66 14.32 25 38713 681 110549880
Nasopharyngitis 90.03 14.32 15 38723 394346 110156215
Psychotic disorder 88.57 14.32 99 38639 50838 110499723
Premature delivery 87.51 14.32 78 38660 30554 110520007
Hepatitis B DNA assay positive 86.72 14.32 17 38721 92 110550469
Peripheral swelling 86.61 14.32 18 38720 404016 110146545
Hepatitis D 86.11 14.32 17 38721 96 110550465
Cushing's syndrome 83.85 14.32 25 38713 905 110549656
Synovitis 82.73 14.32 3 38735 274089 110276472
Hydrops foetalis 79.21 14.32 23 38715 758 110549803
Premature rupture of membranes 77.18 14.32 36 38702 4601 110545960
Blood creatine phosphokinase increased 76.07 14.32 110 38628 72967 110477594
Acute HIV infection 74.69 14.32 14 38724 57 110550504
Pulmonary tuberculosis 74.53 14.32 44 38694 9095 110541466
Portal hypertension 74.17 14.32 43 38695 8594 110541967
Dyspnoea 73.30 14.32 176 38562 1106696 109443865
Ophthalmoplegia 73.19 14.32 32 38706 3518 110547043
Rebound effect 73.09 14.32 52 38686 14754 110535807
Wheezing 73.07 14.32 4 38734 255226 110295335
Pneumonia 72.92 14.32 122 38616 876592 109673969
Gene mutation 70.99 14.32 31 38707 3398 110547163
Trisomy 18 70.65 14.32 20 38718 601 110549960
Systemic lupus erythematosus 69.78 14.32 5 38733 254333 110296228
Musculoskeletal stiffness 67.63 14.32 9 38729 279813 110270748
Cleft lip and palate 67.40 14.32 20 38718 712 110549849
Sinusitis 66.13 14.32 12 38726 296676 110253885
Wound 66.11 14.32 4 38734 234433 110316128
Pericarditis 64.10 14.32 3 38735 219111 110331450
Hepatic cirrhosis 63.50 14.32 97 38641 67529 110483032
Brain stem stroke 61.85 14.32 19 38719 762 110549799
Lipoatrophy 61.34 14.32 18 38720 616 110549945
Placental disorder 60.84 14.32 20 38718 1001 110549560
Osteopenia 60.38 14.32 55 38683 22154 110528407
Mitochondrial cytopathy 60.15 14.32 16 38722 379 110550182
Placental insufficiency 60.01 14.32 21 38717 1273 110549288
Malaria 58.91 14.32 16 38722 411 110550150
Stomatitis 57.97 14.32 12 38726 270230 110280331
Placenta praevia 57.32 14.32 18 38720 777 110549784
Cytomegalovirus chorioretinitis 57.30 14.32 34 38704 7094 110543467
Immune reconstitution inflammatory syndrome associated tuberculosis 56.25 14.32 19 38719 1035 110549526
Swelling 55.15 14.32 27 38711 351014 110199547
Glomerular filtration rate decreased 55.06 14.32 59 38679 28897 110521664
Fatigue 54.71 14.32 230 38508 1215728 109334833
Blood alkaline phosphatase increased 54.65 14.32 93 38645 70842 110479719
Oligohydramnios 54.33 14.32 27 38711 3967 110546594
Lower respiratory tract infection 53.81 14.32 10 38728 243096 110307465
Hepatic function abnormal 53.51 14.32 105 38633 89190 110461371
Haemolytic anaemia 53.37 14.32 50 38688 20870 110529691
Hepatitis 52.88 14.32 105 38633 89949 110460612
Hepatic cancer 52.36 14.32 38 38700 11118 110539443
Acquired immunodeficiency syndrome 52.14 14.32 14 38724 344 110550217
Retinal toxicity 51.36 14.32 20 38718 1639 110548922
Contusion 50.80 14.32 10 38728 233351 110317210
Ocular icterus 48.99 14.32 29 38709 6024 110544537
Helicobacter infection 48.68 14.32 4 38734 181873 110368688
Blood lactic acid increased 48.62 14.32 42 38696 15779 110534782
Impaired healing 48.31 14.32 6 38732 196711 110353850
Asthma 48.06 14.32 14 38724 250277 110300284
Suicidal ideation 47.50 14.32 103 38635 93834 110456727
Fall 47.35 14.32 87 38651 603395 109947166
Off label use 47.32 14.32 320 38418 1499865 109050696
Osteoporotic fracture 46.97 14.32 27 38711 5310 110545251
Kaposi's sarcoma 46.91 14.32 15 38723 687 110549874
Arthralgia 46.86 14.32 130 38608 779502 109771059
Oesophageal candidiasis 46.79 14.32 36 38702 11498 110539063
Hepatitis C 46.17 14.32 37 38701 12536 110538025
Foetal death 46.11 14.32 41 38697 16004 110534557
Injury 44.54 14.32 5 38733 177260 110373301
Varices oesophageal 44.30 14.32 29 38709 7186 110543375
Hepatic encephalopathy 44.19 14.32 52 38686 28204 110522357
Nervous system disorder 42.51 14.32 54 38684 31667 110518894
Ultrasound antenatal screen abnormal 42.43 14.32 9 38729 76 110550485
Arthropathy 42.37 14.32 24 38714 287498 110263063
Blood pressure increased 41.91 14.32 19 38719 258354 110292207
Hepatic steatosis 41.61 14.32 67 38671 48764 110501797
Blister 41.36 14.32 14 38724 227362 110323199
Constipation 40.90 14.32 39 38699 357747 110192814
Adrenal suppression 40.62 14.32 17 38721 1679 110548882
Product use issue 40.51 14.32 30 38708 311665 110238896
Gamma-glutamyltransferase increased 40.31 14.32 75 38663 61234 110489327
COVID-19 39.78 14.32 18 38720 245042 110305519
Metabolic acidosis 39.10 14.32 99 38639 99645 110450916
Folliculitis 39.08 14.32 6 38732 167647 110382914
Hepatic fibrosis 39.05 14.32 28 38710 8038 110542523
Premature baby 38.61 14.32 23 38715 4832 110545729
Blood phosphorus abnormal 38.53 14.32 11 38727 341 110550220
HIV associated nephropathy 38.22 14.32 11 38727 351 110550210
Malaise 38.17 14.32 115 38623 671704 109878857
Ill-defined disorder 37.99 14.32 5 38733 156848 110393713
Muscle injury 37.95 14.32 3 38735 140804 110409757
Polydipsia 37.94 14.32 27 38711 7661 110542900
Myalgia 37.59 14.32 166 38572 222215 110328346
Lymphadenopathy 36.96 14.32 74 38664 63761 110486800
Malignant neoplasm progression 36.91 14.32 8 38730 174559 110376002
Dry mouth 36.91 14.32 12 38726 199936 110350625
Beta 2 microglobulin urine increased 36.71 14.32 9 38729 152 110550409
CSF virus identified 36.17 14.32 7 38731 35 110550526
Mobility decreased 36.17 14.32 19 38719 237403 110313158
Completed suicide 36.04 14.32 20 38718 242361 110308200
Dysphagia 35.95 14.32 127 38611 153473 110397088
Spina bifida 35.66 14.32 9 38729 172 110550389
Retroviral rebound syndrome 35.50 14.32 6 38732 11 110550550
Hepatitis fulminant 35.35 14.32 27 38711 8533 110542028
Dyslipidaemia 34.79 14.32 35 38703 15930 110534631
Blood creatine phosphokinase MB increased 34.75 14.32 18 38720 2885 110547676
Discomfort 34.49 14.32 16 38722 214691 110335870
AIDS cholangiopathy 34.23 14.32 6 38732 15 110550546
Injection site pain 34.06 14.32 10 38728 177912 110372649
Dialysis 33.87 14.32 38 38700 19581 110530980
Alopecia 33.85 14.32 47 38691 364706 110185855
Antiviral drug level below therapeutic 33.57 14.32 7 38731 54 110550507
Polyuria 33.47 14.32 36 38702 17702 110532859
Cerebral toxoplasmosis 33.41 14.32 18 38720 3124 110547437
Anal cancer 33.09 14.32 12 38726 807 110549754
Drug reaction with eosinophilia and systemic symptoms 32.72 14.32 82 38656 82013 110468548
Hypertriglyceridaemia 32.64 14.32 34 38704 16120 110534441
Rash maculo-papular 32.64 14.32 77 38661 74145 110476416
Blood bicarbonate decreased 32.46 14.32 22 38716 5775 110544786
Febrile neutropenia 32.31 14.32 38 38700 316729 110233832
Musculoskeletal pain 32.04 14.32 12 38726 183011 110367550
Blood antidiuretic hormone increased 31.94 14.32 7 38731 70 110550491
Bursitis 31.80 14.32 4 38734 129914 110420647
Joint range of motion decreased 31.73 14.32 3 38735 121829 110428732
Nephrogenic diabetes insipidus 31.70 14.32 16 38722 2429 110548132
Oxygen saturation decreased 31.60 14.32 8 38730 156974 110393587
Live birth 31.55 14.32 73 38665 69411 110481150
Product dose omission issue 31.35 14.32 40 38698 321742 110228819
Lymphoma 31.34 14.32 37 38701 20134 110530427
Transaminases increased 30.34 14.32 68 38670 63322 110487239
Osteoarthritis 30.29 14.32 13 38725 182610 110367951
Hypotension 30.22 14.32 89 38649 523760 110026801
Syphilis 30.01 14.32 11 38727 763 110549798
Progressive multifocal leukoencephalopathy 29.59 14.32 40 38698 24916 110525645
Blood cholesterol increased 29.33 14.32 14 38724 184771 110365790
Retroperitoneal disorder 29.04 14.32 6 38732 44 110550517
Hepatosplenomegaly 28.96 14.32 22 38716 6897 110543664
Pre-eclampsia 28.70 14.32 24 38714 8626 110541935
Pulmonary embolism 28.70 14.32 20 38718 214454 110336107
Inappropriate schedule of product administration 28.58 14.32 18 38720 203619 110346942
Therapeutic product effect incomplete 28.48 14.32 22 38716 223783 110326778
Shoulder arthroplasty 28.46 14.32 17 38721 3590 110546971
Cholestasis 28.44 14.32 67 38671 64451 110486110
Cough 28.42 14.32 76 38662 461565 110088996
Maternal drugs affecting foetus 28.30 14.32 13 38725 1604 110548957
C-reactive protein increased 28.27 14.32 21 38717 217898 110332663
Hepatotoxicity 28.12 14.32 66 38672 63334 110487227
Pancreatitis acute 28.11 14.32 64 38674 60210 110490351
Tubulointerstitial nephritis 27.98 14.32 60 38678 54224 110496337
Autoimmune hepatitis 27.85 14.32 30 38708 14774 110535787
Hyperphosphaturia 27.73 14.32 7 38731 134 110550427
Arthritis 27.68 14.32 12 38726 167574 110382987
Abdominal pain upper 27.64 14.32 50 38688 349061 110201500
Toxoplasmosis 27.48 14.32 16 38722 3223 110547338
Creatinine renal clearance decreased 27.45 14.32 36 38702 21779 110528782
Viral load decreased 27.38 14.32 5 38733 17 110550544
Pathological fracture 27.37 14.32 27 38711 12005 110538556
Hepatorenal syndrome 27.07 14.32 18 38720 4579 110545982
Hypersensitivity 26.81 14.32 64 38674 403934 110146627
Blood HIV RNA 26.75 14.32 5 38733 20 110550541
Muscle spasms 26.65 14.32 35 38703 278122 110272439
HIV test positive 26.64 14.32 7 38731 158 110550403
Pneumocystis jirovecii pneumonia 26.50 14.32 51 38687 42684 110507877
Viraemia 26.44 14.32 17 38721 4085 110546476
Stress 26.39 14.32 3 38735 105345 110445216
Foetal cardiac disorder 26.36 14.32 5 38733 22 110550539
Polyhydramnios 26.09 14.32 13 38725 1920 110548641
Abnormal dreams 26.00 14.32 27 38711 12753 110537808
Weight increased 25.89 14.32 69 38669 419575 110130986
Cachexia 25.61 14.32 27 38711 12978 110537583
Liver function test abnormal 25.54 14.32 67 38671 68883 110481678
Eyelid oedema 25.39 14.32 29 38709 15233 110535328
Hypouricaemia 25.35 14.32 9 38729 569 110549992
Mycobacterium avium complex infection 25.29 14.32 19 38719 5858 110544703
Calculus urinary 25.24 14.32 15 38723 3137 110547424
Atrial fibrillation 25.11 14.32 26 38712 229616 110320945
Influenza 25.07 14.32 14 38724 169087 110381474
Rickets 25.02 14.32 6 38732 92 110550469
Hypoaesthesia 24.87 14.32 45 38693 314178 110236383
Bone pain 24.85 14.32 64 38674 65069 110485492
Gastrointestinal disorder 24.69 14.32 29 38709 241923 110308638
Benign hydatidiform mole 24.66 14.32 6 38732 98 110550463
Anaphylactic reaction 24.65 14.32 5 38733 114295 110436266
Pancytopenia 24.49 14.32 141 38597 209472 110341089
Pain in extremity 24.45 14.32 88 38650 487030 110063531
Dizziness 24.43 14.32 144 38594 698049 109852512
Secondary syphilis 24.38 14.32 6 38732 103 110550458
Rhabdomyolysis 24.36 14.32 95 38643 120306 110430255
Meningitis cryptococcal 24.14 14.32 17 38721 4745 110545816
Ectopic pregnancy 23.98 14.32 13 38725 2284 110548277
Ascites 23.68 14.32 79 38659 92729 110457832
Mitochondrial myopathy 23.51 14.32 8 38730 446 110550115
Type III hyperlipidaemia 23.44 14.32 4 38734 8 110550553
Blood triglycerides increased 23.42 14.32 35 38703 23891 110526670
Hepatomegaly 23.40 14.32 33 38705 21381 110529180
Melanoderma 23.23 14.32 8 38730 462 110550099
Dermatitis exfoliative 23.13 14.32 24 38714 11323 110539238
Disease progression 23.08 14.32 31 38707 244003 110306558
Kidney fibrosis 23.01 14.32 16 38722 4376 110546185
Gynaecomastia 22.90 14.32 22 38716 9468 110541093
Bradycardia 22.87 14.32 13 38725 155504 110395057
CSF test abnormal 22.82 14.32 9 38729 763 110549798
Splenomegaly 22.79 14.32 35 38703 24463 110526098
Seroconversion test positive 22.72 14.32 5 38733 51 110550510
Acute hepatitis C 22.54 14.32 7 38731 291 110550270
Hand deformity 22.50 14.32 26 38712 218480 110332081
Hepatitis A 22.48 14.32 10 38728 1145 110549416
Renal aneurysm 22.45 14.32 7 38731 295 110550266
Acidosis hyperchloraemic 22.40 14.32 11 38727 1575 110548986
Hepatitis cholestatic 22.12 14.32 29 38709 17537 110533024
Cerebellar syndrome 21.98 14.32 18 38720 6284 110544277
Limb operation 21.88 14.32 15 38723 4009 110546552
Migraine 21.68 14.32 17 38721 171635 110378926
Urine phosphorus increased 21.63 14.32 6 38732 167 110550394
Psoriasis 21.62 14.32 11 38727 139982 110410579
Cholestasis of pregnancy 21.61 14.32 10 38728 1255 110549306
Nephropathy 21.41 14.32 25 38713 13442 110537119
Oesophageal varices haemorrhage 21.31 14.32 16 38722 4929 110545632
Urine uric acid increased 21.27 14.32 5 38733 70 110550491
Anaemia 21.08 14.32 288 38450 546798 110003763
Vitamin D deficiency 20.88 14.32 29 38709 18523 110532038
Memory impairment 20.75 14.32 23 38715 196921 110353640
Psychomotor retardation 20.60 14.32 19 38719 7773 110542788
Haemodialysis 20.40 14.32 28 38710 17691 110532870
Meningomyelocele 20.35 14.32 4 38734 22 110550539
Haemophilic arthropathy 20.29 14.32 6 38732 211 110550350
Portal fibrosis 20.07 14.32 8 38730 697 110549864
ACTH stimulation test abnormal 19.91 14.32 4 38734 25 110550536
Inflammation 19.89 14.32 23 38715 193215 110357346
Lymphocytic infiltration 19.87 14.32 11 38727 2014 110548547
Nasal congestion 19.79 14.32 5 38733 98277 110452284
Chest discomfort 19.79 14.32 19 38719 173829 110376732
Anaemia macrocytic 19.68 14.32 18 38720 7285 110543276
Hyperlactacidaemia 19.60 14.32 19 38719 8267 110542294
Anogenital warts 19.47 14.32 9 38729 1127 110549434
Bone density decreased 19.45 14.32 26 38712 16016 110534545
Chromaturia 19.40 14.32 36 38702 29324 110521237
Abortion infected 19.28 14.32 4 38734 30 110550531
Renal disorder 19.27 14.32 49 38689 49430 110501131
Bronchitis 19.27 14.32 16 38722 157016 110393545
Blood pressure systolic increased 19.27 14.32 3 38735 82988 110467573
White matter lesion 19.22 14.32 12 38726 2742 110547819
Nodular regenerative hyperplasia 19.20 14.32 10 38728 1621 110548940
Heart rate decreased 19.19 14.32 3 38735 82753 110467808
Blood bilirubin unconjugated increased 19.13 14.32 9 38729 1172 110549389
Pulmonary fibrosis 19.05 14.32 6 38732 102036 110448525
Urine calcium increased 18.98 14.32 5 38733 114 110550447
Oropharyngeal pain 18.92 14.32 12 38726 135264 110415297
Hodgkin's disease 18.90 14.32 8 38730 812 110549749
Obesity 18.90 14.32 8 38730 113343 110437218
Cortisol decreased 18.89 14.32 12 38726 2824 110547737
Tuberculosis 18.84 14.32 27 38711 17747 110532814
Unmasking of previously unidentified disease 18.77 14.32 12 38726 2856 110547705
Anion gap abnormal 18.75 14.32 8 38730 828 110549733
Burkitt's lymphoma 18.66 14.32 5 38733 122 110550439
Pulmonary oedema 18.65 14.32 6 38732 100653 110449908
Disseminated tuberculosis 18.59 14.32 15 38723 5131 110545430
Portal venous gas 18.57 14.32 7 38731 525 110550036
Injection site erythema 18.57 14.32 5 38733 94171 110456390
Meningitis tuberculous 18.46 14.32 9 38729 1269 110549292
HIV infection 18.29 14.32 9 38729 1294 110549267
Pancreatitis 18.27 14.32 73 38665 93460 110457101
Nephrocalcinosis 18.20 14.32 10 38728 1804 110548757
Acute hepatitis B 18.14 14.32 7 38731 560 110550001
Feeling abnormal 18.07 14.32 22 38716 180689 110369872
Sleep disorder 18.01 14.32 26 38712 198618 110351943
Pregnancy on oral contraceptive 17.95 14.32 8 38730 920 110549641
Skin lesion 17.94 14.32 49 38689 51582 110498979
Liver transplant 17.91 14.32 14 38724 4575 110545986
Upper respiratory tract infection 17.89 14.32 12 38726 131316 110419245
Amylase increased 17.87 14.32 22 38716 12497 110538064
Bone metabolism disorder 17.87 14.32 7 38731 583 110549978
Twin pregnancy 17.71 14.32 8 38730 950 110549611
Gestational diabetes 17.59 14.32 17 38721 7372 110543189
Oedema 17.59 14.32 29 38709 209947 110340614
Hyperbilirubinaemia neonatal 17.58 14.32 3 38735 6 110550555
Glycocholic acid increased 17.58 14.32 3 38735 6 110550555
Carbon dioxide combining power abnormal 17.58 14.32 3 38735 6 110550555
Hydromyelia 17.58 14.32 3 38735 6 110550555
Rhinorrhoea 17.52 14.32 7 38731 102659 110447902
General physical health deterioration 17.48 14.32 83 38655 425212 110125349
Metabolic syndrome 17.41 14.32 12 38726 3235 110547326
Neoplasm progression 17.39 14.32 56 38682 64539 110486022
Lipohypertrophy 17.33 14.32 8 38730 998 110549563
Cystitis viral 17.25 14.32 9 38729 1464 110549097
Hyperparathyroidism secondary 17.22 14.32 12 38726 3292 110547269
AIDS related complication 17.22 14.32 4 38734 53 110550508
Neck pain 17.11 14.32 11 38727 123119 110427442
Illness 16.90 14.32 4 38734 82167 110468394
Drug hypersensitivity 16.75 14.32 92 38646 453998 110096563
Vth nerve injury 16.72 14.32 3 38735 9 110550552
Back pain 16.69 14.32 70 38668 370926 110179635
Acidosis 16.64 14.32 29 38709 22502 110528059
Lipase increased 16.43 14.32 26 38712 18646 110531915
Anembryonic gestation 16.21 14.32 6 38732 428 110550133
Pharyngeal cancer 16.13 14.32 4 38734 71 110550490
Hepatitis B surface antibody 16.05 14.32 3 38735 12 110550549
Oesophageal carcinoma 16.05 14.32 20 38718 11504 110539057
Drug ineffective for unapproved indication 16.00 14.32 8 38730 102830 110447731
HIV wasting syndrome 15.92 14.32 4 38734 75 110550486
Pleocytosis 15.92 14.32 9 38729 1715 110548846
Lung disorder 15.90 14.32 24 38714 180023 110370538
Prognathism 15.85 14.32 3 38735 13 110550548
Optic nerve cupping 15.82 14.32 4 38734 77 110550484
Relapsing fever 15.77 14.32 6 38732 462 110550099
Road traffic accident 15.76 14.32 9 38729 107389 110443172
Red blood cell sedimentation rate increased 15.73 14.32 4 38734 78298 110472263
Necrotising enterocolitis neonatal 15.67 14.32 3 38735 14 110550547
Hepatitis B core antibody 15.67 14.32 3 38735 14 110550547
Congenital diaphragmatic hernia 15.50 14.32 3 38735 15 110550546
Dyspepsia 15.42 14.32 27 38711 190938 110359623
Blood corticotrophin decreased 15.40 14.32 7 38731 843 110549718
Pneumonitis 15.21 14.32 4 38734 76527 110474034
CD4 lymphocytes abnormal 15.19 14.32 4 38734 91 110550470
Trisomy 21 15.19 14.32 4 38734 91 110550470
Erectile dysfunction 15.18 14.32 25 38713 18531 110532030
Cranial nerve palsies multiple 15.18 14.32 5 38733 252 110550309
Contraindicated product administered 15.16 14.32 41 38697 248226 110302335
Renal injury 15.03 14.32 25 38713 18688 110531873
Dysphonia 15.03 14.32 4 38734 75925 110474636
Encephalitis 14.90 14.32 25 38713 18814 110531747
Lower limb fracture 14.85 14.32 4 38734 75344 110475217
Acute respiratory failure 14.83 14.32 4 38734 75256 110475305
Hepatitis D RNA positive 14.77 14.32 3 38735 20 110550541
Femoral neck fracture 14.68 14.32 20 38718 12547 110538014
Chronic hepatitis B 14.65 14.32 6 38732 561 110550000
Mesenteric artery thrombosis 14.64 14.32 7 38731 946 110549615
Portal vein thrombosis 14.52 14.32 15 38723 7043 110543518
Atypical mycobacterial infection 14.47 14.32 10 38728 2708 110547853
Cardiac failure congestive 14.46 14.32 19 38719 150981 110399580
Cervix haemorrhage uterine 14.40 14.32 3 38735 23 110550538
Castleman's disease 14.40 14.32 3 38735 23 110550538
Death 14.40 14.32 166 38572 698703 109851858
Joint stiffness 14.38 14.32 3 38735 67240 110483321

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC J05AR03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR24 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR27 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:53756 HIV-1 reverse transcriptase inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:50864 insulin-sensitizing drug

Related Drugs by ATC class:

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 12 drugs
abacaviradefovir dipivoxilclevudinedidanosineemtricitabineentecavirlamivudinestavudinetelbivudinetenofovir alafenamidezalcitabinezidovudine
J05AR Antivirals for treatment of HIV infections, combinations 19 drugs
abacaviratazanavirbictegravircobicistatdarunavirdolutegravirdoravirineefavirenzelvitegraviremtricitabinelamivudinelopinavir show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Osteomalacia contraindication 4598005 DOID:10573
Hypophosphatemia contraindication 4996001
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Torsades de pointes contraindication 31722008
Depressive disorder contraindication 35489007
Fanconi syndrome contraindication 40488004 DOID:1062
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Prolonged QT interval contraindication 111975006
Chronic hepatitis C contraindication 128302006
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Paranoid disorder contraindication 191667009
Steatosis of liver contraindication 197321007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Severe depression contraindication 310497006
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.86 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
600MG;200MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 DISCN TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 DISCN TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 DISCN TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 DISCN TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 7176220 Aug. 27, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 7635704 Oct. 26, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 9891239 Sept. 3, 2029 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8633219 April 30, 2030 TREATMENT OF HIV INFECTION
100MG;300MG;300MG DELSTRIGO MSD MERCK CO N210807 Aug. 30, 2018 RX TABLET ORAL 8486975 Aug. 30, 2032 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
100MG;300MG;300MG DELSTRIGO MSD MERCK CO N210807 Aug. 30, 2018 RX TABLET ORAL 8486975 Aug. 30, 2032 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO
100MG;300MG;300MG DELSTRIGO MSD MERCK CO N210807 Aug. 30, 2018 RX TABLET ORAL 8486975 Aug. 30, 2032 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prolyl endopeptidase FAP Enzyme Ki 6.05 CHEMBL
Reverse transcriptase/RNaseH Enzyme INHIBITOR CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein WOMBAT-PK

External reference:

IDSource
D01982 KEGG_DRUG
202138-50-9 SECONDARY_CAS_RN
4021279 VANDF
4021280 VANDF
C0384228 UMLSCUI
TFO PDB_CHEM_ID
CHEMBL1538 ChEMBL_ID
CHEMBL1486 ChEMBL_ID
D000068698 MESH_DESCRIPTOR_UI
DB00300 DRUGBANK_ID
F4YU4LON7I UNII
5481350 PUBCHEM_CID
DB14126 DRUGBANK_ID
117466 RXNORM
16193 MMSL
267164 MMSL
29323 MMSL
42402 MMSL
d04774 MMSL
009357 NDDF
009358 NDDF
017389 NDDF
385556006 SNOMEDCT_US
395264002 SNOMEDCT_US
421203005 SNOMEDCT_US
422091007 SNOMEDCT_US
CHEBI:63718 CHEBI
206184-49-8 SECONDARY_CAS_RN
464205 PUBCHEM_CID
CHEBI:63716 CHEBI
F4YU4LON7I INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DELSTRIGO HUMAN PRESCRIPTION DRUG LABEL 3 0006-5007 TABLET, FILM COATED 300 mg ORAL NDA 32 sections
DELSTRIGO HUMAN PRESCRIPTION DRUG LABEL 3 0006-5007 TABLET, FILM COATED 300 mg ORAL NDA 32 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 3 0093-5234 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0093-7704 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 3 0378-5440 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
tenofovir disoproxil fumarate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6821 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0904-7172 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 2 16714-534 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Tenofovir Disoproxil Fumarate Human Prescription Drug Label 1 16714-820 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 31722-535 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Emtricitabine and tenofovir disoproxil fumarate HUMAN PRESCRIPTION DRUG LABEL 2 31722-560 TABLET, FILM COATED 300 mg ORAL ANDA 26 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 3 31722-736 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
tenofovir disoproxil fumarate Human Prescription Drug Label 1 33342-096 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 2 33342-106 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 33342-138 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 1 42291-800 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 42291-980 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
emtricitabine, rilpivirine and tenofovir disoproxil fumarate Human Prescription Drug Label 3 42385-801 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Tenofovir Disoproxil Fumarate Human Prescription Drug Label 1 42385-901 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Efavirenz, emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 3 42385-915 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 42385-928 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 42385-929 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 2 42385-953 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 42543-719 TABLET 300 mg ORAL ANDA 27 sections
SYMFI LO HUMAN PRESCRIPTION DRUG LABEL 3 49502-425 TABLET, FILM COATED 300 mg ORAL NDA 32 sections
CIMDUO HUMAN PRESCRIPTION DRUG LABEL 2 49502-450 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
SYMFI HUMAN PRESCRIPTION DRUG LABEL 3 49502-475 TABLET, FILM COATED 300 mg ORAL NDA 31 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 50090-0870 TABLET, FILM COATED 300 mg ORAL NDA 32 sections
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE HUMAN PRESCRIPTION DRUG LABEL 2 50090-5957 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 2 50090-6494 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections